Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

1. Clinical Overview

Summary

Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) is a chronic debilitating condition characterised by persistent pelvic pain, pressure, or discomfort perceived to be related to the bladder, accompanied by at least one other urinary symptom such as urgency or frequency, in the absence of infection or other identifiable pathology. [1,2,3] The condition requires symptoms to persist for at least 6 weeks to establish chronicity and distinguish it from acute inflammatory or infectious processes.

The pathophysiology remains incompletely understood but is thought to involve multifactorial mechanisms including:

• Glycosaminoglycan (GAG) layer deficiency leading to increased urothelial permeability
• Mast cell activation and neurogenic inflammation
• Urothelial dysfunction with upregulation of sensory nerve pathways
• Central sensitisation contributing to chronic pain perpetuation [4,5,6]

IC/BPS demonstrates significant female predominance (9:1 female-to-male ratio) and typically presents in the third to fifth decades of life. The condition exists on a spectrum with two distinct phenotypes: Hunner lesion IC (classic type, ~10% of cases) characterised by inflammatory patches visible on cystoscopy, and non-Hunner IC (BPS, ~90%) which may show glomerulations or normal cystoscopic appearance. [7,9]

Diagnosis is clinical and based on exclusion of other pathology including urinary tract infection, bladder malignancy, urolithiasis, and gynaecological conditions. Cystoscopy with hydrodistension is not mandatory for diagnosis but may be performed to exclude other pathology and identify Hunner lesions when present. [2,3,7]

Management requires a multimodal, stepwise approach including:

1. Lifestyle modifications – dietary triggers, stress management, bladder training
2. Oral pharmacotherapy – amitriptyline, pentosan polysulphate sodium, antihistamines
3. Intravesical therapy – DMSO, heparin, hyaluronic acid for GAG layer replenishment
4. Interventional procedures – hydrodistension, fulguration/injection of Hunner lesions, neuromodulation
5. Psychological support – addressing comorbid depression and anxiety [2,7,10]

The condition is chronic and relapsing with significant impact on quality of life, relationships, and occupational function. While spontaneous remission occurs in 10-20% of patients, most require long-term multimodal management to achieve symptom control. [3,17]

Clinical Pearls

Diagnosis of Exclusion: IC/BPS cannot be diagnosed until UTI, bladder cancer, urolithiasis, and other specific pathology are excluded. Sterile pyuria is common.

Pain-Voiding Relationship: The hallmark is pain related to bladder filling that is relieved by voiding. This distinguishes IC/BPS from other chronic pelvic pain conditions.

Hunner Lesions Predict Treatment Response: The ~10% of patients with Hunner lesions (classic IC) often respond dramatically to fulguration or intralesional steroid injection, whereas non-Hunner type requires multimodal systemic therapy. [9]

GAG Layer as Therapeutic Target: Both oral (pentosan polysulphate) and intravesical (heparin, hyaluronic acid) therapies aim to restore the protective glycosaminoglycan layer, though clinical efficacy varies significantly. [4,12]

Dietary Triggers Are Real: While mechanisms remain unclear, 90% of patients report symptom exacerbation with specific foods/drinks. The "IC diet" (avoiding caffeine, alcohol, acidic/spicy foods, artificial sweeteners) is first-line conservative management. [14]

Overlap with Other Syndromes: IC/BPS frequently coexists with fibromyalgia, IBS, chronic fatigue syndrome, and vulvodynia – suggesting shared central sensitisation pathways. [5,6]

Pentosan Polysulphate Maculopathy: Long-term use (> 15 years or cumulative dose > 1,500g) is associated with pigmentary maculopathy. Ophthalmology screening is now recommended for long-term users. [11]

---

2. Epidemiology

Prevalence and Incidence

Risk Factors and Associations

Disease Burden and Quality of Life Impact

Exam Detail: IC/BPS causes profound quality of life impairment comparable to rheumatoid arthritis and chronic renal failure:

• Sleep disruption: Nocturia 3-10 times per night in severe cases
• Sexual dysfunction: Dyspareunia in > 60% of women; erectile dysfunction and painful ejaculation in men
• Occupational impact: Frequent absenteeism, inability to work in severe cases
• Social isolation: Embarrassment, inability to travel, relationship strain
• Economic burden: High healthcare utilisation; lost productivity costs estimated at $65,000-$100,000 per patient lifetime in US cohorts [17]

---

3. Aetiology and Pathophysiology

Proposed Pathophysiological Mechanisms

The pathophysiology of IC/BPS is multifactorial and incompletely understood. Current theories implicate overlapping mechanisms involving the urothelium, neurogenic inflammation, immune dysregulation, and central nervous system pain processing. [4,5,6]

1. Glycosaminoglycan (GAG) Layer Deficiency

The GAG layer is a protective mucopolysaccharide coating on the bladder urothelium composed of hyaluronic acid, chondroitin sulphate, and heparan sulphate. This layer:

• Prevents adherence of bacteria and irritants
• Forms a hydrophobic barrier preventing urinary constituents from penetrating the urothelium
• Inhibits nerve activation by maintaining urothelial impermeability [4]

In IC/BPS, GAG layer deficiency leads to:

• Increased urothelial permeability to urinary potassium, urea, and other irritants
• Direct activation of subepithelial sensory nerves (C-fibres) → pain and urgency
• Potassium Sensitivity Test (Parsons test) – instillation of potassium chloride solution reproduces pain in IC/BPS patients (though no longer routinely used due to poor specificity) [4]

Evidence: Histological studies demonstrate reduced GAG layer thickness and altered proteoglycan composition in IC/BPS bladders. This forms the rationale for GAG replenishment therapies (pentosan polysulphate orally, heparin/hyaluronic acid intravesically). [4,10]

2. Urothelial Dysfunction and Increased Permeability

Beyond GAG deficiency, the urothelium itself shows functional abnormalities:

• Tight junction disruption: Reduced expression of occludin and zonula occludens proteins → "leaky urothelium"
• Upregulation of sensory receptors: Increased expression of purinergic (P2X3), vanilloid (TRPV1), and nerve growth factor (NGF) receptors on urothelial cells
• Abnormal urothelial cell differentiation: Loss of umbrella cell integrity [5,6]

This creates a vicious cycle: Permeability defect → Inflammation → Further urothelial damage → Persistent pain and symptoms.

3. Neurogenic Inflammation and Mast Cell Activation

Mast cells are found in increased numbers in IC/BPS bladder biopsies, particularly in proximity to nerves and blood vessels. [6]

Mast cell degranulation releases:

• Histamine → vasodilation, oedema, nerve activation
• Tryptase → protease-activated receptor (PAR) activation → inflammation
• Substance P → neurogenic inflammation amplification
• Nerve Growth Factor (NGF) → sensory nerve sprouting and sensitisation
• Cytokines (TNF-α, IL-6) → chronic inflammation [6]

Clinical correlate: Antihistamines (hydroxyzine) provide modest benefit in some patients, supporting the mast cell hypothesis. [2,7]

Neurogenic inflammation involves activation of C-fibre afferents → antidromic release of neuropeptides (substance P, CGRP) → further mast cell activation, creating a self-perpetuating inflammatory loop. [6]

4. Central Sensitisation and Pain Amplification

Chronic pain conditions including IC/BPS involve central nervous system changes that amplify and maintain pain independently of peripheral input:

• Spinal cord dorsal horn sensitisation: Increased excitability of second-order neurons (wind-up phenomenon)
• Loss of descending inhibition: Reduced serotonergic and noradrenergic inhibitory control
• Cortical reorganisation: Altered pain processing in anterior cingulate cortex, insula, and prefrontal cortex
• Comorbid pain syndromes: Explains overlap with fibromyalgia, IBS, chronic fatigue, migraines [5,6]

Clinical implications:

• Pain may persist despite successful peripheral treatment (e.g., post-fulguration of Hunner lesions)
• Central neuromodulators (amitriptyline, gabapentin) are more effective than peripheral bladder treatments in some patients
• Multimodal approach addressing both peripheral bladder pathology and central pain processing is essential [7,10]

5. Autoimmune and Infectious Triggers

Autoimmune hypothesis:

• Some patients have circulating autoantibodies against bladder tissue
• Associations with systemic autoimmune diseases (SLE, Sjögren's)
• Bladder biopsies may show lymphocytic infiltration
• However, no consistent autoimmune marker identified, and immunosuppression (cyclosporine) shows limited efficacy [5]

Infectious trigger hypothesis:

• Some cases report onset following documented UTI
• Molecular mimicry – bacterial antigens may trigger autoimmune response
• Occult infection theories largely unproven; standard cultures negative
• Antibiotic trials show no benefit in IC/BPS [5]

Histopathological Features

Key point: IC/BPS is not a muscle disease (unlike detrusor overactivity). It is a urothelial and sensory nerve pathology. [5,6]

Subtypes: Hunner Lesion vs Non-Hunner IC/BPS

Clinical significance: Identifying Hunner lesions is critical as these patients may achieve dramatic benefit from targeted lesion destruction (laser, electrocautery, steroid injection), whereas non-Hunner type requires systemic multimodal therapy. [7,9]

---

4. Clinical Presentation

Cardinal Symptom Triad

Duration criterion: Symptoms must persist ≥6 weeks to meet chronic pain criteria and exclude acute causes. [2,3,7]

Associated Symptoms and Features

Symptom Variability and Phenotypes

IC/BPS is heterogeneous. Symptom patterns vary:

• Pain-predominant: Severe bladder/pelvic pain; frequency moderate
• Frequency-predominant: Extreme urgency/frequency (every 20-30 mins); pain less prominent
• Mixed: Both equally severe
• Hunner lesion: Often most severe pain and smallest capacity (less than 300ml) [9]

Examination Findings

General examination: Usually unremarkable systemically.

Abdominal examination:

• Suprapubic tenderness on palpation (common)
• Palpable bladder if retention (rare; IC/BPS typically causes frequency, not retention)
• Exclude masses, organomegaly

Pelvic/Vaginal examination (women):

• Pelvic floor hypertonicity: Increased tone, tenderness of levator ani on digital examination
• Anterior vaginal wall tenderness: Bladder base tenderness through anterior vaginal wall
• Trigger points: Myofascial trigger points in obturator internus, levator ani
• Exclude gynaecological pathology: endometriosis, masses, prolapse

Urological examination (men):

• Digital rectal examination: Prostate tenderness (chronic prostatitis/CPPS overlap)
• Exclude prostatitis, prostatic mass

Neurological examination: Normal (unless comorbid neurological disease). Exclude spinal pathology if lower limb symptoms present.

---

5. Differential Diagnosis

IC/BPS is a diagnosis of exclusion. The following conditions must be considered and excluded:

Diagnostic Approach: Excluding Mimics

The diagnostic pathway is:

1. Clinical suspicion: Chronic bladder pain + urgency/frequency ≥6 weeks
2. Urine dipstick + culture: Exclude infection (culture negative; may have pyuria)
3. Urine cytology: If haematuria, age > 50, smoking – exclude CIS/cancer
4. Bladder diary: Quantify frequency, volumes, pain severity
5. Imaging (if indicated): Ultrasound for stones/post-void residual; CT/MRI if mass suspected
6. Cystoscopy: Not mandatory, but recommended if:
   • Haematuria (exclude malignancy)
   • Age > 40 with new-onset symptoms (exclude cancer)
   • Atypical features
   • Failure to respond to initial treatment
   • To identify Hunner lesions (changes management) [2,7]

If all above negative/normal + chronic symptoms ≥6 weeks → Diagnosis of IC/BPS

---

6. Investigations

Baseline Investigations: Exclude Other Pathology

Cystoscopy ± Hydrodistension

Indications (not mandatory for diagnosis, but often performed): [2,7]

• Haematuria (exclude malignancy)
• Age > 40 with new onset symptoms (cancer exclusion)
• Failure to respond to initial conservative treatment
• Atypical features (rapid progression, systemic symptoms)
• Identify Hunner lesions (changes management to fulguration)

Technique:

• Performed under general or regional anaesthesia (allows hydrodistension)
• Hydrodistension: Bladder filled to 80-100 cmH₂O for 1-2 minutes under gravity
• Findings documented:
  • "Hunner lesions: Erythematous patches with central pallor/fibrin; may crack and bleed on distension"
  • "Glomerulations: Petechial haemorrhages appearing after hydrodistension (non-specific; seen in other conditions and even normal individuals)"
  • "Bladder capacity: Measure maximal capacity under anaesthesia (normal ~400-600ml; less than 350ml suggests severe IC)"
  • "Exclude: Tumours, stones, fistulae, foreign bodies"

Biopsy: Not routine unless lesion suspicious for malignancy. In Hunner lesion IC, biopsy shows ulceration, inflammation, fibrosis. [7,9]

Cystoscopic Findings

Important: Normal cystoscopy does not rule out IC/BPS. Diagnosis is clinical. [2,7]

Potassium Sensitivity Test (Parsons Test)

Principle: Instil potassium chloride (KCl) solution into bladder. Normal urothelium is impermeable; defective GAG layer allows K⁺ to penetrate → pain/urgency.

Technique: Instil 40ml water (control), then 40ml KCl 0.4M solution. Positive if pain/urgency significantly worse with KCl.

Status: No longer routinely used. Poor specificity (false positives in OAB, normal individuals). Painful and poorly tolerated. [4]

Urodynamics

Not routinely indicated in IC/BPS. May be considered if:

• Diagnostic uncertainty (OAB vs IC/BPS)
• Coexisting voiding dysfunction suspected
• Pre-operative assessment before invasive procedures

Typical findings:

• Bladder hypersensitivity: First sensation and strong desire to void at low volumes
• Normal detrusor function: No involuntary contractions (distinguishes from detrusor overactivity)
• Pain during filling: Patients report pain at low volumes
• Small functional capacity: Due to pain, not anatomical limitation [2]

Specialist Investigations

---

7. Management

Management Principles

IC/BPS requires a chronic disease management approach with:

1. Realistic expectations: No cure; goal is symptom control and improved quality of life
2. Multimodal strategy: Combination of lifestyle, pharmacological, and procedural interventions
3. Stepwise escalation: Conservative → oral → intravesical → procedural
4. Individualised treatment: Phenotype-specific (Hunner vs non-Hunner); patient preferences
5. Psychological support: Address comorbid depression, anxiety, catastrophising
6. Multidisciplinary team: Urology, pain medicine, physiotherapy, psychology [2,7,10]

Management Algorithm

       SUSPECTED IC/BPS
       (Bladder Pain + Urgency + Frequency ≥6 weeks)
                     ↓
       CONFIRM DIAGNOSIS
       - Exclude UTI (urine culture)
       - Exclude malignancy (cytology if indicated, cystoscopy if high risk)
       - Bladder diary
       - Consider cystoscopy if: haematuria, age > 40, atypical, treatment failure
                     ↓
       IC/BPS DIAGNOSIS CONFIRMED
                     ↓
┌──────────────────────────────────────────────────────────────────┐
│  FIRST-LINE: LIFESTYLE & CONSERVATIVE MANAGEMENT                 │
│  (All patients)                                                  │
├──────────────────────────────────────────────────────────────────┤
│  1. PATIENT EDUCATION                                            │
│     - Chronic condition; no quick cure                           │
│     - Self-management strategies                                 │
│     - Support groups (IC associations)                           │
│                                                                  │
│  2. DIETARY MODIFICATION ("IC Diet")                             │
│     - AVOID: Caffeine, Alcohol, Acidic foods (citrus, tomatoes), │
│       Spicy foods, Artificial sweeteners, Chocolate             │
│     - Food diary: Identify personal triggers                     │
│     - Gradual reintroduction after symptom control               │
│                                                                  │
│  3. STRESS MANAGEMENT                                            │
│     - Relaxation techniques, Mindfulness, CBT                    │
│     - Stress is major flare trigger                              │
│                                                                  │
│  4. BLADDER TRAINING                                             │
│     - Gradual increase in voiding intervals                      │
│     - Target: Void every 2-3 hours (when comfortable)            │
│     - Reduce "preventative" voiding                              │
│                                                                  │
│  5. PELVIC FLOOR PHYSIOTHERAPY                                   │
│     - If pelvic floor hypertonicity present                      │
│     - Manual therapy, trigger point release, biofeedback         │
│     - Improves pain, dyspareunia, voiding                        │
│                                                                  │
│  Duration: 6-12 weeks trial                                      │
└──────────────────────────────────────────────────────────────────┘
                     ↓
       INADEQUATE RESPONSE?
                     ↓
┌──────────────────────────────────────────────────────────────────┐
│  SECOND-LINE: ORAL PHARMACOTHERAPY                               │
│  (Select based on predominant symptom and patient factors)       │
├──────────────────────────────────────────────────────────────────┤
│  1. AMITRIPTYLINE (First choice oral agent)                      │
│     - Dose: Start 10mg nocte, titrate to 25-75mg                 │
│     - Mechanism: Central neuromodulation; reduces pain, urgency  │
│     - Benefits: Also improves sleep, mood                        │
│     - Side effects: Dry mouth, drowsiness, constipation, weight  │
│       gain                                                       │
│     - Trial: 3-6 months (slow onset)                             │
│                                                                  │
│  2. PENTOSAN POLYSULPHATE SODIUM (Elmiron)                       │
│     - Dose: 100mg TDS orally                                     │
│     - Mechanism: GAG layer replenishment (oral heparinoid)       │
│     - Onset: 3-6 months (very slow)                              │
│     - Efficacy: Modest (30-40% response rate)                    │
│     - Side effects: GI upset, headache, alopecia (rare)          │
│     - CRITICAL WARNING: **Pigmentary Maculopathy**               │
│       - Risk with long-term use (> 15 years or > 1,500g cumulative)│
│       - Baseline + annual ophthalmology review recommended       │
│                                                                  │
│  3. HYDROXYZINE (Antihistamine)                                  │
│     - Dose: 25-50mg nocte                                        │
│     - Mechanism: Mast cell stabilisation; H1 blockade            │
│     - Benefits: Sedating (helps sleep); anxiolytic               │
│     - Trial: 3 months                                            │
│                                                                  │
│  4. CIMETIDINE (H2 Blocker)                                      │
│     - Dose: 200-400mg BD                                         │
│     - Mechanism: Mast cell H2 blockade                           │
│     - Limited evidence; less effective than hydroxyzine          │
│                                                                  │
│  5. GABAPENTIN / PREGABALIN (Neuropathic pain)                   │
│     - If neuropathic pain component                              │
│     - Gabapentin 300mg TDS, titrate to 900-1,800mg/day           │
│     - Side effects: Sedation, dizziness, weight gain             │
│                                                                  │
│  Duration: 3-6 month trial each agent (slow onset typical)       │
│  Combination therapy: Often use amitriptyline + pentosan         │
└──────────────────────────────────────────────────────────────────┘
                     ↓
       INADEQUATE RESPONSE?
                     ↓
┌──────────────────────────────────────────────────────────────────┐
│  THIRD-LINE: INTRAVESICAL THERAPY                                │
│  (Requires catheterisation; specialist urology input)            │
├──────────────────────────────────────────────────────────────────┤
│  1. DMSO (Dimethyl Sulfoxide)                                    │
│     - Dose: 50ml instillation (50% DMSO solution)                │
│     - Frequency: Weekly x 6 weeks, then PRN maintenance          │
│     - Mechanism: Anti-inflammatory, analgesic, muscle relaxant,  │
│       mast cell inhibition                                       │
│     - Efficacy: 50-70% response (best evidence of intravesicals) │
│     - Side effects: Garlic taste/breath (metabolite), chemical   │
│       cystitis (transient flare first 24-48h)                    │
│                                                                  │
│  2. HEPARIN ± LIDOCAINE ("Rescue Instills")                      │
│     - Dose: Heparin 10,000-20,000 units + Lidocaine 2% 10ml      │
│     - Frequency: Daily to weekly, patient self-administered      │
│     - Mechanism: GAG layer replacement + local anaesthetic       │
│     - Benefits: Rapid onset (lidocaine); patient-controlled      │
│     - Duration: Hold 15-30 mins then void                        │
│                                                                  │
│  3. HYALURONIC ACID ± CHONDROITIN SULPHATE (e.g., iAluRil, Cystistat) │
│     - Dose: 40-50ml instillation                                 │
│     - Frequency: Weekly x 4-8 weeks, then monthly maintenance    │
│     - Mechanism: GAG layer replenishment                         │
│     - Efficacy: Variable (40-60% response); expensive            │
│     - Benefits: Well tolerated; low side effects                 │
│                                                                  │
│  Duration: 6-12 week trial; if effective, continue maintenance   │
│  Combination: Can combine DMSO with heparin/HA protocols         │
└──────────────────────────────────────────────────────────────────┘
                     ↓
       STILL REFRACTORY? OR HUNNER LESIONS IDENTIFIED?
                     ↓
┌──────────────────────────────────────────────────────────────────┐
│  FOURTH-LINE: INTERVENTIONAL / SPECIALIST PROCEDURES             │
│  (Specialist urology / pain medicine referral)                   │
├──────────────────────────────────────────────────────────────────┤
│  1. CYSTOSCOPY WITH HYDRODISTENSION                              │
│     - Bladder distension to 80-100cmH₂O for 2-3 minutes          │
│     - Mechanism: Disrupts sensory nerves; increases capacity     │
│     - Efficacy: 20-50% benefit; short duration (3-6 months)      │
│     - May repeat if benefit demonstrated                         │
│                                                                  │
│  2. FULGURATION / INJECTION OF HUNNER LESIONS                    │
│     - Laser ablation or electrocautery of lesions                │
│     - ± Intralesional steroid (triamcinolone) injection          │
│     - Efficacy: **60-90% excellent response** in Hunner type     │
│     - Duration: 12-24 months; lesions recur → repeat treatment   │
│     - ONLY for Hunner lesion IC                                  │
│                                                                  │
│  3. BOTULINUM TOXIN A (BOTOX) INTRADETRUSOR INJECTION            │
│     - Dose: 100-200 units (multiple sites in bladder wall)       │
│     - Mechanism: Reduces sensory nerve activity, muscle spasm    │
│     - Efficacy: 40-60% benefit; off-label use                    │
│     - Duration: 6-12 months; repeat injections needed            │
│     - Risk: Urinary retention (5-10%); voiding difficulty        │
│                                                                  │
│  4. NEUROMODULATION                                              │
│     a) Sacral Nerve Stimulation (SNS)                            │
│        - Permanent implant; modulates S3 nerve root              │
│        - Efficacy: 50-70% benefit in refractory cases            │
│        - Trial period (percutaneous test) before permanent       │
│     b) Posterior Tibial Nerve Stimulation (PTNS)                 │
│        - Non-invasive; weekly sessions x 12 weeks                │
│        - Efficacy: Modest; less invasive option                  │
│                                                                  │
│  5. CYCLOSPORINE A (Immunosuppressant)                           │
│     - Dose: 3mg/kg/day in divided doses                          │
│     - Mechanism: Immune modulation (autoimmune hypothesis)       │
│     - Efficacy: 75% response in one RCT, but limited replication│
│     - Side effects: Nephrotoxicity, hypertension, infection risk │
│     - Requires specialist monitoring (renal function, BP)        │
│     - Reserved for severe refractory cases                       │
│                                                                  │
│  6. CYSTECTOMY + URINARY DIVERSION (Last resort)                 │
│     - Indications: Intractable pain; failed all other treatments;│
│       severe contracted bladder; patient well-informed           │
│     - Procedures: Ileal conduit, continent diversion, neobladder │
│     - Outcomes: 60-80% pain improvement (NOT 100%)               │
│     - WARNING: 20-40% have persistent pain post-cystectomy       │
│       (central sensitisation persists)                           │
│     - Requires careful patient selection, psychological support  │
└──────────────────────────────────────────────────────────────────┘
                     ↓
       THROUGHOUT ALL STAGES:
       - Psychological support (CBT, pain psychology)
       - Treat comorbid depression/anxiety (SSRIs if needed)
       - Pelvic floor physiotherapy
       - Pain medicine input (multimodal analgesia)
       - Patient support groups

Treatment Summary Table

Exam Detail: ### Evidence Base for Key Treatments

Amitriptyline:

• Tricyclic antidepressant; modulates central pain pathways via serotonin/noradrenaline reuptake inhibition
• Reduces neuropathic pain, improves sleep (beneficial given nocturia), treats comorbid depression
• Low-dose (10-75mg) used; lower than antidepressant doses (150mg+)
• Side effects: anticholinergic (dry mouth, constipation, urinary retention – paradoxical in IC/BPS but rare); sedation; weight gain
• Evidence: Multiple small RCTs and cohort studies show benefit; recommended by AUA and EAU guidelines [2,7,10]

Pentosan Polysulphate Sodium (PPS / Elmiron):

• Synthetic heparinoid; excreted in urine; binds to urothelial surface → GAG layer restoration
• Only FDA-approved oral medication specifically for IC/BPS (1996)
• Efficacy: Modest. Meta-analysis shows 30-40% response vs placebo [12]
• Very slow onset: 3-6 months minimum trial essential
• Pigmentary Maculopathy: Identified 2018-2020; cumulative dose-dependent (> 1,500g or > 15 years use) retinal toxicity causing vision impairment; NOW requires ophthalmology monitoring [11]
• Current recommendation: Use with caution; informed consent; baseline + annual eye exams [11,12]

DMSO (Dimethyl Sulfoxide):

• Intravesical instillation; 50% solution; 50ml weekly x 6 weeks
• Mechanisms: Anti-inflammatory, analgesic, collagenase inhibition, mast cell inhibition, muscle relaxation
• Best evidence of all intravesical therapies: RCTs show 50-70% symptom improvement [13,14]
• Metabolised to dimethyl sulphide → garlic taste/breath (warn patients)
• Transient flare: First 24-48h post-instillation (chemical cystitis) then improvement
• Well tolerated; repeatable; can use for maintenance PRN [13]

Hunner Lesion Fulguration/Injection:

• Transformative for Hunner lesion IC (but only ~10% have lesions) [9]
• Techniques: Laser (Nd:YAG, KTP, Holmium), electrocautery, ± intralesional steroid (triamcinolone 40mg)
• Response: 60-90% marked improvement in pain, frequency, capacity [9]
• Duration: 12-24 months; lesions recur in 50-70% → repeat treatment effective
• Does NOT work for non-Hunner IC (no lesions to treat)
• Key message: Always look for Hunner lesions on cystoscopy – changes management entirely [7,9]

Cyclosporine:

• Immunosuppressant (calcineurin inhibitor)
• One landmark RCT (Sairanen et al): 75% response vs 19% placebo, BUT small study (64 patients) and not widely replicated [7]
• Significant side effects: nephrotoxicity (renal function monitoring), hypertension, infection risk, hirsutism, gingival hyperplasia
• Reserved for severe refractory cases where other treatments failed; specialist use only
• Dose: 3mg/kg/day in divided doses; trough level monitoring [7]

Cystectomy:

• Last resort only. Not curative.
• Pain persistence: 20-40% have ongoing pelvic pain post-cystectomy due to central sensitisation (pain pathways established independently of bladder)
• Better outcomes if: Hunner lesion type; small contracted bladder; pain strictly bladder-related
• Worse outcomes if: Widespread pelvic pain; fibromyalgia overlap; psychological comorbidity
• Requires: Extensive pre-operative counselling, psychological assessment, pain team input, realistic expectations
• Urinary diversion options: Ileal conduit (urostomy bag), continent cutaneous (catheterisable pouch), orthotopic neobladder (if urethra pain-free)
• Bottom line: Avoid if possible; only if truly intractable bladder-specific pain and patient fully informed [7]

Management of Hunner Lesion vs Non-Hunner IC/BPS

Key point: Identifying Hunner lesions is critical – these patients have a specific treatable target. Cystoscopy should be considered in all patients not responding to initial treatment. [7,9]

Adjunctive and Supportive Management

What NOT to Do

---

8. Complications and Disease Impact

Direct Complications

Quality of Life and Psychosocial Impact

Overall QOL: Comparable to rheumatoid arthritis, chronic renal failure, chronic angina on validated scales (SF-36). [17]

---

9. Prognosis and Outcomes

Natural History

Treatment Outcomes

Conservative + Oral therapies: 40-60% achieve meaningful improvement (not cure) with multimodal approach (diet + amitriptyline + PPS ± intravesicals). [7,10]

Hunner Lesion Fulguration: 60-90% excellent response, but lesions recur in 50-70% requiring repeat treatment. [9]

Neuromodulation (SNS): 50-70% benefit in refractory cases; durable over years; requires permanent implant. [7]

Cystectomy: 60-80% pain improvement, BUT 20-40% have persistent pain (central sensitisation). Not curative. [7]

Prognostic Factors

Long-term Outcomes

• No cure exists for IC/BPS currently
• Majority require lifelong management with combinations of therapies
• Symptom control is achievable in most with multimodal approach
• Quality of life can be significantly improved with appropriate treatment and support
• Multidisciplinary care (urology, pain medicine, physiotherapy, psychology) produces best outcomes [2,7,10,17]

---

10. Evidence and Guidelines

Key Clinical Practice Guidelines

Landmark Studies and Evidence

Levels of Evidence for Key Treatments

---

11. Patient and Layperson Explanation

What is Interstitial Cystitis / Bladder Pain Syndrome?

Interstitial Cystitis (IC), also called Bladder Pain Syndrome (BPS), is a long-term (chronic) condition that causes:

• Pain in the bladder or pelvic area – often described as pressure, aching, or burning
• Needing to urinate very frequently – sometimes every hour, or even more often
• Sudden, strong urges to urinate – feeling like you need to rush to the toilet
• Waking up multiple times at night to pass urine

The pain typically gets worse as your bladder fills with urine, and feels better after you empty your bladder. This is different from a normal urinary infection, which causes burning when you urinate and can be cured with antibiotics. IC/BPS is not an infection – urine tests are usually clear.

What causes it?

Doctors don't fully understand what causes IC/BPS, but the leading theory is that the protective lining inside the bladder is damaged. Normally, this lining (called the glycosaminoglycan or "GAG" layer) acts like a waterproof barrier, stopping irritating chemicals in urine from reaching the bladder wall. In IC/BPS, this barrier is leaky, so urine irritates the bladder, causing pain, inflammation, and hypersensitive nerves.

Other factors may include:

• Overactive immune system or inflammation
• Oversensitive nerves in the bladder
• Chronic pain changes in the brain and spinal cord (similar to other chronic pain conditions)

It is NOT caused by infection, and it is NOT contagious. It is more common in women than men (9 out of 10 people with IC/BPS are women).

How is it diagnosed?

There is no single test for IC/BPS. Instead, doctors diagnose it by:

1. Ruling out other problems – urine tests to exclude infection, and sometimes a camera test (cystoscopy) to look inside the bladder and make sure there's no cancer, stones, or other issues
2. Listening to your symptoms – if you have bladder pain, urgency, and frequency for more than 6 weeks, and tests are normal, IC/BPS is likely
3. Bladder diary – recording how often you urinate and how much pain you have helps confirm the diagnosis

Some patients (~10%) have visible red, inflamed patches inside the bladder called Hunner's lesions. These can be seen during a cystoscopy and can be treated directly.

How is it treated?

IC/BPS is a chronic condition with no quick cure, but symptoms can be controlled with a combination of treatments. The approach is:

Step 1: Lifestyle changes (everyone should try these first)

• Avoid trigger foods and drinks: Caffeine, alcohol, fizzy drinks, spicy foods, citrus fruits, tomatoes, and artificial sweeteners often make symptoms worse. Keep a food diary to find your personal triggers.
• Manage stress: Stress can cause flare-ups. Relaxation techniques, mindfulness, or counselling can help.
• Bladder training: Gradually increasing the time between toilet visits can help retrain your bladder.
• Pelvic floor physiotherapy: Special exercises and physiotherapy can help if your pelvic floor muscles are tight or painful.

Step 2: Medications

• Amitriptyline: A low-dose antidepressant that helps reduce pain and urgency, and improves sleep. It takes several weeks to work.
• Pentosan polysulphate (Elmiron): A tablet that helps repair the bladder lining. It takes 3-6 months to work, and long-term use requires regular eye checks due to a rare side effect affecting vision.
• Antihistamines: Sometimes used to reduce inflammation inside the bladder.

Step 3: Bladder treatments If tablets don't help enough, your doctor may suggest bladder instillations – putting medication directly into the bladder through a small catheter (tube). Examples include:

• DMSO: An anti-inflammatory liquid (causes a garlic taste/smell as a side effect)
• Heparin or hyaluronic acid: Help repair the bladder lining

Step 4: Procedures (for severe cases)

• Bladder stretching (hydrodistension): Done under anaesthetic; the bladder is gently stretched, which can provide temporary relief.
• Treating Hunner's lesions: If you have the visible red patches, your doctor can burn them away (fulguration) or inject them with steroids – this can give excellent relief.
• Nerve stimulation: A device implanted near the tailbone sends gentle electrical signals to calm overactive bladder nerves.
• Botox injections: Injected into the bladder wall to reduce pain and urgency.

Surgery (bladder removal) is a last resort and only considered in very severe cases that don't respond to anything else.

Will it get better?

IC/BPS is usually a long-term condition. Most people have good days and bad days, with symptom flares triggered by diet, stress, or other factors. However, with the right combination of treatments, most people can control their symptoms and improve their quality of life significantly.

Some people (about 10-20%) do experience spontaneous improvement or even remission, but this is unpredictable.

Where can I get support?

• Patient support groups: The Interstitial Cystitis Association (ICA) and local bladder pain support groups provide information, peer support, and coping strategies.
• Counselling/therapy: Living with chronic pain is difficult. Cognitive behavioural therapy (CBT) and chronic pain management programmes can help you cope better.
• Specialist care: Ask your GP or urologist to refer you to a specialist IC/BPS clinic if symptoms are severe or not improving with initial treatments.

Key message

IC/BPS is a real medical condition – you are not imagining it, and it is not "all in your head". It is caused by physical changes in your bladder. With patience, the right treatments, and support, you can gain control over your symptoms and live well despite this condition.

---

12. Examination Focus

High-Yield Viva / OSCE Questions and Model Answers

Q1: What is the hallmark symptom pattern that distinguishes IC/BPS from other bladder conditions?

Model Answer: The hallmark of IC/BPS is pelvic pain, pressure, or discomfort perceived to be related to the bladder, which is:

• Related to bladder filling – pain worsens as the bladder fills
• Relieved by voiding – pain improves after emptying the bladder
• Accompanied by urgency and frequency (often > 8 voids/day, nocturia ≥2)
• Symptoms persist ≥6 weeks (chronic)
• No evidence of infection or other identifiable pathology (sterile urine)

This filling-voiding pain relationship distinguishes IC/BPS from overactive bladder (urgency/frequency but NO pain) and UTI (acute onset, positive culture). [2,3,7]

---

Q2: A 38-year-old woman presents with 12 months of suprapubic pain, urinary frequency (15x/day), and nocturia (5x/night). Urine culture is negative. What is your diagnostic approach?

Model Answer:

Diagnosis: Suspected IC/BPS based on chronic bladder pain + frequency + sterile urine.

Diagnostic Approach (diagnosis of exclusion):

1. History: Duration ≥6 weeks ✓; bladder-filling pain pattern; triggers (diet, stress); impact on QOL; screen for comorbidities (fibromyalgia, IBS, depression)
2. Examination: Suprapubic tenderness; pelvic exam to exclude gynaecological pathology, assess pelvic floor tone
3. Investigations:
   • Urinalysis + culture: Exclude UTI (already done – negative ✓)
   • Urine cytology: If haematuria, age > 50, or smoker – exclude bladder cancer/CIS
   • Bladder diary: Quantify frequency, voided volumes, pain scores
   • Post-void residual: Exclude retention (expect low/normal in IC/BPS)
   • Cystoscopy: Not mandatory, but consider if haematuria, age > 40, or treatment failure. Look for Hunner lesions (changes management)
4. Diagnosis confirmed if all investigations normal/negative + chronic symptoms

Initial Management:

• First-line conservative: Dietary modification (avoid caffeine, alcohol, acidic/spicy foods), stress management, bladder training, pelvic floor physiotherapy
• Second-line oral: Amitriptyline 10mg nocte, titrate to 25-75mg (3-6 month trial)
• Review in 6-12 weeks; escalate to intravesical therapies or cystoscopy if inadequate response [2,7]

---

Q3: What are Hunner lesions, and why are they clinically important in IC/BPS management?

Model Answer:

Hunner Lesions are:

• Erythematous (red), inflamed patches or ulcers on the bladder mucosa
• Seen on cystoscopy in ~10% of IC/BPS patients (Classic IC phenotype)
• Often have central pallor, fibrinous exudate, and may crack and bleed during hydrodistension
• Associated with more severe symptoms: intense pain, frequency, reduced bladder capacity (less than 350ml)

Clinical Importance:

1. Diagnostic: Confirm IC diagnosis (though absence does NOT exclude IC/BPS)
2. Prognostic: Hunner lesion IC is more severe but also more treatable
3. Therapeutic target: Lesions can be fulgrated (laser/electrocautery) or injected with steroids
   • Excellent response: 60-90% marked symptom improvement
   • Duration: 12-24 months; lesions recur but re-treatment effective
4. Changes management: If Hunner lesions present → fulguration is first-line procedural treatment; if absent → multimodal medical/intravesical therapy

Bottom line: Always look for Hunner lesions on cystoscopy – identifies a highly treatable subgroup. [7,9]

---

Q4: A patient with IC/BPS has been on pentosan polysulphate (Elmiron) for 8 years. What monitoring is required and why?

Model Answer:

Pentosan Polysulphate (PPS) is an oral GAG layer replenishment therapy for IC/BPS.

Risk: Pigmentary Maculopathy (retinal toxicity)

• Mechanism: Cumulative dose-dependent; PPS deposits in retina → macular pigmentary changes → vision impairment
• Risk factors: Long-term use (> 15 years), high cumulative dose (> 1,500g)
• Presentation: Difficulty reading, dark adaptation problems, paracentral scotomas (blind spots)
• Identified: 2018-2020 case series linked PPS to maculopathy [11]

Monitoring Required:

1. Baseline ophthalmology exam before starting PPS
2. Annual ophthalmology review including:
   • Fundoscopy: Look for pigmentary changes in macula
   • OCT (Optical Coherence Tomography): Macular structure
   • Visual field testing: Detect scotomas
3. Patient counselling: Inform of risk; report any vision changes immediately
4. Consider discontinuation if maculopathy detected (though damage may be irreversible)

Current recommendation: Use PPS with caution; weigh benefits vs risk of retinal toxicity; ensure ophthalmology monitoring in place. [11,12]

---

Q5: When would you consider cystectomy for IC/BPS, and what are the outcomes?

Model Answer:

Cystectomy (bladder removal + urinary diversion) is a last resort for IC/BPS.

Indications (all must be met):

• Intractable pain severely impacting quality of life
• Failed ALL other treatments: Conservative, oral, intravesical, procedural (hydrodistension, fulguration, Botox, neuromodulation)
• Bladder-centric pain (pain specifically related to bladder; NOT widespread pelvic pain)
• Ideally small contracted bladder (less than 300ml) or severe Hunner lesion disease
• Patient fully informed of risks/benefits
• Psychological assessment completed; realistic expectations

Contraindications/Poor candidates:

• Widespread pelvic pain (suggests central sensitisation → pain will persist post-cystectomy)
• Comorbid fibromyalgia, IBS, chronic pain syndromes (central sensitisation dominant)
• Severe psychological comorbidity without support
• Young age (irreversible; lifelong consequences)

Outcomes:

• Pain improvement: 60-80% report significant pain reduction
• Pain persistence: 20-40% have ongoing pelvic pain despite bladder removal (central sensitisation, pelvic floor, urethra)
• NOT curative; pain may persist
• Quality of life: Urinary diversion (stoma or catheterisable pouch) has own challenges (body image, appliance management, complications)

Bottom line: Cystectomy is NOT a guarantee of pain relief and is irreversible. Only consider after exhaustive trial of all other therapies, in carefully selected patients, with extensive pre-operative counselling and psychological support. [7]

---

Examination Pearls

Diagnosis: IC/BPS is clinical and by exclusion. Chronic bladder pain + urgency/frequency + sterile urine = IC/BPS (after excluding UTI, cancer, stones).

Pain Pattern: Filling-related pain, relieved by voiding = IC/BPS hallmark.

Hunner Lesions: ~10% of IC/BPS. Fulguration gives 60-90% response. Always look for them on cystoscopy.

GAG Layer: Protective bladder lining; defective in IC/BPS → urothelial permeability → pain. Target of PPS (oral) and heparin/HA (intravesical).

First-line Oral: Amitriptyline (25-75mg nocte). Central neuromodulation; also improves sleep/mood.

Best Intravesical: DMSO (50% solution, weekly x6). Anti-inflammatory. 50-70% response. Garlic taste side effect.

PPS Eye Risk: Pigmentary maculopathy with long-term use (> 15 years). Annual ophthalmology monitoring required.

Multimodal is Key: No single treatment works for all. Combine lifestyle + oral + intravesical + psychology for best outcomes.

Overlap Syndromes: IC/BPS frequently coexists with fibromyalgia, IBS, chronic fatigue, vulvodynia → shared central sensitisation pathways.

Cystectomy Caveat: 20-40% have persistent pain post-op (central sensitisation). NOT curative. Last resort only.

---

13. Related Topics and Further Reading

Related MedVellum Topics

• Chronic Pelvic Pain Syndromes – Broader overview of CPP; multidisciplinary management
• Overactive Bladder Syndrome – Differential diagnosis; anticholinergic therapy
• Urinary Tract Infections – Recurrent UTI vs IC/BPS differentiation
• Bladder Cancer – Red flag exclusion; cystoscopy findings
• Endometriosis – Pelvic pain; cyclical symptoms; bladder involvement
• Chronic Pain Management – Central sensitisation; neuromodulation; psychology
• Fibromyalgia – Overlap syndrome; shared pathophysiology
• Depression and Anxiety – Comorbidity management; CBT; pharmacotherapy

Key Guidelines and Consensus Statements

1. American Urological Association (AUA): Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome (2022) [7]
2. European Association of Urology (EAU): Guidelines on Chronic Pelvic Pain (2024) [2]
3. Japanese Urological Association: Clinical Guidelines for Interstitial Cystitis/Bladder Pain Syndrome (2020, updated 2023) [3]

Landmark Reviews

• Theoharides TC et al. Interstitial cystitis: a neuroimmunoendocrine disorder (1998) – Pathophysiology review [6]
• Giannantoni A et al. Contemporary management of the painful bladder: a systematic review (2011) – Treatment overview [17]
• Whitmore KE et al. Hunner lesion versus non-Hunner lesion IC/BPS (2019) – Phenotype differentiation [9]

---

14. References

Primary Sources

1. Li J, et al. Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome. Biomedicines. 2022;10(11):2867. PMID: 36498919. DOI: 10.3390/biomedicines10112867

2. Beltran E, et al. Female Pelvic Conditions: Interstitial Cystitis/Bladder Pain Syndrome. FP Essent. 2024;547:11-17. PMID: 39692795.

3. Homma Y, et al. Definition Change and Update of Clinical Guidelines for Interstitial Cystitis and Hypersensitive Bladder Syndrome in Japan. Int J Urol. 2024. PMID: 39267358. DOI: 10.1111/iju.15581

4. Wyndaele JJJ, et al. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535-544. PMID: 30592544. DOI: 10.1002/nau.23900

5. Daniels AM, et al. Interstitial Cystitis: An Update on the Disease Process and Treatment. Curr Urol Rep. 2018;19(11):89. PMID: 30212267. DOI: 10.1007/s11934-018-0846-6

6. Theoharides TC, et al. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann N Y Acad Sci. 1998;840:619-634. PMID: 9629289. DOI: 10.1111/j.1749-6632.1998.tb09600.x

7. Clemens JQ, et al. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2022;208(1):34-42. PMID: 35536143. DOI: 10.1097/JU.0000000000002756 [AUA Guideline]

8. [Duplicate citation removed]

9. Whitmore KE, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26 Suppl 1:26-34. PMID: 31144757. DOI: 10.1111/iju.13993

10. [Duplicate citation removed]

11. Lindeke-Myers A, et al. Pentosan polysulfate maculopathy. Curr Opin Ophthalmol. 2021;32(3):248-254. PMID: 34000253. DOI: 10.1097/ICU.0000000000000759

12. van Ophoven A, et al. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomised clinical trials. Curr Med Res Opin. 2019;35(8):1479-1484. PMID: 30849922. DOI: 10.1080/03007995.2019.1590365

13. Rawls WF, et al. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: a review. Neurourol Urodyn. 2017;36(7):1677-1684. PMID: 28220525. DOI: 10.1002/nau.23204

14. Almeida FG, et al. Interstitial cystitis - intravesical treatment. Int Braz J Urol. 2019;45(4):651-659. PMID: 31066806. DOI: 10.1590/S1677-5538.IBJU.2019.0396

15. Meng E, et al. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Transl Androl Urol. 2017;6(Suppl 2):S171-S179. PMID: 29341502. DOI: 10.21037/tau.2017.06.18

16. Moreno-Ligero M, et al. mHealth Intervention for Improving Pain, Quality of Life, and Functional Disability in Patients With Chronic Pelvic Pain: Randomized Controlled Trial. J Med Internet Res. 2023;25:e43609. PMID: 36729570. DOI: 10.2196/43609

17. Giannantoni A, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29-53. PMID: 21920661. DOI: 10.1016/j.eururo.2011.07.069

18. Lai HH, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Bladder Pain Syndrome, and Pelvic Floor Myalgia. J Urol. 2025. PMID: 40243102. DOI: 10.1016/j.juro.2025.01.068

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local guidelines, and specialist input. Always consult appropriate specialists for complex cases. The information provided reflects current evidence at the time of writing but medical practice evolves; verify current guidelines before clinical application.